Targeting specific pathways to reduce nerve damage from chemotherapy
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
This study is looking at ways to help prevent nerve damage and improve thinking skills in people receiving cisplatin chemotherapy for ovarian cancer, so they can feel better and have a better quality of life after treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10875414 on NIH RePORTER |
What this research studies
This research investigates how to prevent nerve damage caused by cisplatin, a common chemotherapy drug used to treat ovarian cancer. It focuses on the negative side effects that many patients experience, such as cognitive impairment and neuropathy, which can significantly affect their quality of life. The study aims to inhibit certain pathways in the body that lead to nerve cell death, using specific small molecule inhibitors. By doing so, the researchers hope to improve patients' cognitive function and reduce pain and mobility issues after chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are women undergoing treatment for ovarian cancer who are experiencing cognitive impairment or nerve damage due to cisplatin.
Not a fit: Patients who are not receiving cisplatin or those who do not experience chemotherapy-related nerve damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate debilitating nerve damage and cognitive issues in cancer patients receiving chemotherapy.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to mitigate nerve damage from chemotherapy, indicating potential for success in this approach.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Bota, Daniela Annenelie — University of California-Irvine
- Study coordinator: Bota, Daniela Annenelie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.